Please find enclose herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.
Thanking you
Yours faithfully
For NATCO Pharma Limited
Chekuri Venkat
Ramesh
Digitally signed by Chekuri Venkat Ramesh DN: c=IN, st=Telangana, 2.5.4.20=90d42e387bd14ec84f24107c38bbe712c77d154e1e954b183b90527df9a5cf15, postalCode=500090, street=SHREE HOMES COLONY , BACHUPALLY , Bachpalle , Medchalmalkajgiri, pseudonym=6bb41d7c451b4872971cc058675f7c8c, serialNumber=f6910746a5f5b7b789b80a6f72d19727f6631efba3de76111828b13e9225 2ebc, o=Personal, cn=Chekuri Venkat Ramesh
Date: 2022.07.25 09:16:37 +05'30'
Ch. Venkat Ramesh
Company Secretary &
Compliance Officer
Ref: PR/ 5 /2022-23
PRESS RELEASE
NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution
(generic for Jevtana Kit®)
Hyderabad, India, July 25, 2022
Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces today that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc's Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit®) for the 60mg/1.5mL (40mg/mL) strength.
Breckenridge and Natco are unable to make further comment regarding the launch date for the product, as that is confidential and cannot be disclosed at this time. According to industry sales data, Jevtana Kit generated annual sales of $303 million during the twelve months ending May 2022.
*All brand names and trademarks are the property of their respective owners.
Forwarded for favor of publication
For NATCO Pharma Limited
Chekuri Venkat Ramesh
Digitally signed by Chekuri Venkat Ramesh DN: c=IN, st=Telangana, 2.5.4.20=90d42e387bd14ec84f24107c38bbe712c77d154e1e954b183b9 0527df9a5cf15, postalCode=500090, street=SHREE HOMES COLONY , BACHUPALLY , Bachpalle , Medchalmalkajgiri, pseudonym=6bb41d7c451b4872971cc058675f7c8c, serialNumber=f6910746a5f5b7b789b80a6f72d19727f6631efba3de7611 1828b13e92252ebc, o=Personal, cn=Chekuri Venkat Ramesh
Date: 2022.07.25 09:16:03 +05'30'
Ch. Venkat Ramesh
Company Secretary &
Compliance Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
Natco Pharma Limited published this content on 25 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 July 2022 04:33:02 UTC.
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Companyâs segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.
NATCO PHARMA LIMITED 
